Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 9/20 | 0.57 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.51 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.51 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.51 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.51 |
| ▸ | HTR7 | P34969 | 4/20 | 0.47 |
| ▸ | ACHE | P22303 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7220616 | 0.89 | NR3C2 (0.59) | NR3C2MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL7214778 | 0.76 | MAPK14 (0.59) | NR3C2MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL27637382 | 0.73 | NR3C2 (0.61) | NR3C2MAPK14 | |
| SCHEMBL4539921 | 0.73 | NR3C2 (1.00) | NR3C2 | |
| SCHEMBL27742800 | 0.72 | MAPK9 (0.51) | NR3C2MAPK14LMNAPOLB | |
| SCHEMBL5353409 | 0.72 | MAPK14 (0.58) | MAPK14MAPK13MAPK12MAPK11HTR7 | |
| SCHEMBL4543395 | 0.71 | NR3C2 (0.62) | NR3C2MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL4537960 | 0.71 | NR3C2 (0.58) | NR3C2MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL2849513 | 0.70 | MAPK14 (0.52) | MAPK14MAPK13MAPK12MAPK11HTR7 | |
| SCHEMBL15503778 | 0.70 | KDM5A (0.51) | NR3C2MAPK14LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6509361-B1 | Inhibit the activity of p38 MAP kinase. Also contemplated by the invention are processes for the preparation of the contemplated compounds and for the use of a contemplated compound in treating a mammalian host having a p38 kinase or | PHARMACIA CORPORATION | 2003-01-21 | — | — | US | disclosed |
| EP-1077971-A1 | 1,5-DIARYL SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS | G.D. SEARLE & CO. (US) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999058523-A1 | 1,5-DIARYL SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS | G.D. SEARLE & CO. (US) | 1999-11-18 | — | — | WO | disclosed |